Galectin-9 ameliorates acute GVH disease through the induction of T-cell apoptosis

Kazuki Sakai, Eri Kawata, Eishi Ashihara, Yoko Nakagawa, Akira Yamauchi, Hisayuki Yao, Rina Nagao, Ruriko Tanaka, Asumi Yokota, Miki Takeuchi, Hideyo Hirai, Shinya Kimura, Mitsuomi Hirashima, Norio Yoshimura, Taira Maekawa

Research output: Contribution to journalArticlepeer-review

33 Citations (Scopus)

Abstract

Galectins comprise a family of animal lectins that differ in their affinity for β-galactosides. Galectin-9 (Gal-9) is a tandem-repeat-type galectin that was recently shown to function as a ligand for T-cell immunoglobin domain and mucin domain-3 (Tim-3) expressed on terminally differentiated CD4+ Th1 cells. Gal-9 modulates immune reactions, including the induction of apoptosis in Th1 cells. In this study, we investigated the effects of Gal-9 in murine models of acute GVH disease (aGVHD). First, we demonstrated that recombinant human Gal-9 inhibit MLR in a dose-dependent manner, involving both Ca2+ influx and apoptosis in T cells. Next, we revealed that recombinant human Gal-9 significantly inhibit the progression of aGVHD in murine BM transplantation models. In conclusion, Gal-9 ameliorates aGVHD, possibly by inducing T-cell apoptosis, suggesting that gal-9 may be an attractive candidate for the treatment of aGVHD.

Original languageEnglish
Pages (from-to)67-75
Number of pages9
JournalEuropean Journal of Immunology
Volume41
Issue number1
DOIs
Publication statusPublished - Jan 2011

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Galectin-9 ameliorates acute GVH disease through the induction of T-cell apoptosis'. Together they form a unique fingerprint.

Cite this